Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults with Obesity or Overweight in SURMOUNT-1","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's SURMOUNT-1 Results Published in the New England Journal of Medicine Show Tirzepatide Achieved Between 16.0% and 22.5% Weight Loss in Adults With Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tirzepatide Demonstrated Significant and Superior Weight Loss Compared to Placebo in two Pivotal Studies","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Phase 2 Results Published in the New England Journal of Medicine Show Orforglipron, a Once-Daily Oral Nonpeptide GLP-1 Receptor Agonist, Achieved up to 14.7% Mean Weight Reduction at 36 Weeks in Adults with Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly to Present New Research in the Treatment of Diabetes and Obesity at the American Diabetes Association's 83rd Scientific Sessions","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Rhythm Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

              Details:

              Imcivree (setmelanotide) is a MC4 receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity. It is being evaluated for the treatment of hypothalamic obesity.

              Lead Product(s): Setmelanotide Acetate

              Therapeutic Area: Nutrition and Weight Loss Product Name: Imcivree

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rhythm Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

              Details:

              Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist, which is investigated for the treatment of treatment for acquired hypothalamic obesity.

              Lead Product(s): Setmelanotide Acetate

              Therapeutic Area: Nutrition and Weight Loss Product Name: Imcivree

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tirzepatide Demonstrated Significant and Superior Weight Loss Compared to Placebo in two Pivotal Studies

              Details:

              Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner. it is being investigated for weight loss in adults with obesity and type 2 diabetes.

              Lead Product(s): Tirzepatide

              Therapeutic Area: Nutrition and Weight Loss Product Name: Mounjaro

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly's Phase 2 Results Published in the New England Journal of Medicine Show Orforglipron, a Once-Daily Oral Nonpeptide GLP-1 Receptor Agonist, Achieved up to 14.7% Mean W...

              Details:

              LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.

              Lead Product(s): Orforglipron Calcium Hydrate

              Therapeutic Area: Nutrition and Weight Loss Product Name: LY3502970

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Chugai Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly to Present New Research in the Treatment of Diabetes and Obesity at the American Diabetes Association's 83rd Scientific Sessions

              Details:

              LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.

              Lead Product(s): Orforglipron Calcium Hydrate

              Therapeutic Area: Nutrition and Weight Loss Product Name: LY3502970

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Chugai Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities

              Details:

              Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single novel molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones.

              Lead Product(s): Tirzepatide

              Therapeutic Area: Nutrition and Weight Loss Product Name: LY3298176

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly's SURMOUNT-1 Results Published in the New England Journal of Medicine Show Tirzepatide Achieved Between 16.0% and 22.5% Weight Loss in Adults With Obesity or Overweig...

              Details:

              Mounjaro (tirzepatide) met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimands.

              Lead Product(s): Tirzepatide

              Therapeutic Area: Nutrition and Weight Loss Product Name: Mounjaro

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA

              Details:

              Based on the results, the pharmacology of LY3298176 (tirzepatide) translates from preclinical to clinical studies. LY3298176 has the potential to deliver clinically meaningful improvement in glycaemic control and body weight.

              Lead Product(s): Tirzepatide

              Therapeutic Area: Nutrition and Weight Loss Product Name: LY3298176

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults with Obesity or Overweight in SURMOUNT-1

              Details:

              For efficacy estimand, participants taking tirzepatide achieved average weight reduction of 16.0%, 21.4%, and 22.5%, compared to placebo. Additionally, 89% and 96% of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo.

              Lead Product(s): Tirzepatide

              Therapeutic Area: Nutrition and Weight Loss Product Name: LY3298176

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY